Mercados españoles cerrados

Veru Inc. (VERU)

NasdaqCM - NasdaqCM Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
0,7001+0,0535 (+8,27%)
Al cierre: 04:00PM EDT
0,6900 -0,01 (-1,44%)
Después del cierre: 07:56PM EDT

Veru Inc.

2916 North Miami Avenue
Suite 1000
Miami, FL 33127
United States
305 509 6897
https://verupharma.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo189

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Dr. Mitchell S. Steiner F.A.C.S., M.D.Chairman, President & CEO885,32kN/A1961
Dr. Harry Fisch F.A.C.S., M.D.Vice Chairman & Chief Corporate OfficerN/AN/A1959
Ms. Michele GrecoCFO & Chief Administrative Officer493,7kN/A1959
Dr. K. Gary Barnette Ph.D.Chief Scientific Officer676,27kN/A1968
Mr. Samuel FischExecutive Director of Investor Relations & Corporate CommunicationsN/AN/AN/A
Mr. Michael J. PurvisExecutive VP, General Counsel & Corporate Strategy and SecretaryN/AN/AN/A
Mr. Kevin J. Gilbert CPA, J.D.Executive Vice President of Corporate DevelopmentN/AN/AN/A
Mr. Martin TaylerExecutive Vice President of FC2 Global Operations180,51kN/A1969
Mr. Philip R. Greenberg J.D.Executive VP & Deputy General CounselN/AN/AN/A
Dr. Domingo Rodriguez M.D.Executive Vice President of Global Clinical OperationsN/AN/A1962
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Gobierno corporativo

El ISS Governance QualityScore de Veru Inc., a día 1 de marzo de 2024, es 9. Las puntuaciones base son Auditoría: 10; Tablero: 8; Derechos de los accionistas: 4; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.